Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses current visualization methods for assessing hair restoration therapy responses, noting imprecision in triangulated measurements and patient dissatisfaction with visible tattoos.

This article reviews the usage, efficacy, side effects, and alternatives of topical bimatoprost 0.03% for dermatological applications but does not present new clinical findings.

This article reports a case where a man's hair regrew after treating actinic keratosis with fluorouracil, suggesting a possible unexpected effect of the treatment.

This study used computer simulations to evaluate the absorption of oral and topical finasteride for treating androgenetic alopecia, finding that topical applications resulted in lower plasma concentrations, suggesting potential viability as a treatment option.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

This review discusses the pathogenesis and treatment of androgenetic alopecia, highlighting genome associations and newer topical formulations, but reports no new clinical results.

This review discusses various biologics for hair aging but reports no agent capable of reversing the natural aging process of hair.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

In this study, adding low-level light therapy to minoxidil significantly improved hair regrowth and patient satisfaction in treating androgenetic alopecia compared to minoxidil alone.

In this study, researchers reviewed literature on topical delivery of finasteride for androgenetic alopecia, finding that liposomal gels with specific additives showed the highest skin permeation rates, suggesting potential for reducing systemic side effects compared to oral formulations.

This study found that topical minoxidil is more effective than placebo in promoting hair growth in androgenetic alopecia, although cosmetically acceptable results occur only in a subset of patients.

This study found that a chitosan-decorated finasteride nanosystem exhibited satisfactory drug release and retention in rat skin, suggesting it could enhance topical delivery for androgenic alopecia treatment.

In this study, the researchers reported that while both propylene glycol and sodium lauryl sulfate enhanced finasteride's skin deposition, ethanol was the only effective enhancer of finasteride's permeation through the skin.

This review examines the efficacy and safety of using minoxidil at concentrations greater than 5% for androgenetic alopecia but reports no new clinical results, emphasizing a need for further research.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This review found that topical finasteride has similar efficacy to oral finasteride in treating male and female pattern hair loss, with fewer systemic side effects, mainly causing localized scalp reactions like irritation and erythema.

This source discusses the aim of the Australian Journal of General Practice to deliver evidence-based information to help Australian general practitioners provide optimal patient care. Results from specific studies are not included.

This study concluded that oral and topical minoxidil have similar overall benefits in treating androgenetic alopecia, but topical minoxidil improved hair density more and had fewer adverse effects.

In this study of female pattern hair loss, oral finasteride 5 mg and topical minoxidil 5% both significantly improved hair density and patient satisfaction over 6 months, outperforming finasteride 2 mg, which showed limited improvement beyond the third month. All treatments were deemed safe.

Minoxidil may help with hair loss caused by cancer treatments.

This study observed that 5% minoxidil milky lotion increased hair density more than the standard solution at 8 weeks in males with androgenetic alopecia, but their efficacy was similar at later visits.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

Topical minoxidil 1% and 2% are twice as effective as placebo for female pattern hair loss.

This review discusses evidence-based treatments for common hair loss forms, noting robust support for androgenetic alopecia therapies but limited long-term data and fewer high-quality studies for alopecia areata and cicatricial alopecias.

This article reviews previous cases and reports of allergic contact dermatitis from minoxidil but does not provide new clinical findings.

In this study, magnesium was observed to penetrate human skin, with hair follicles significantly aiding this process depending on the concentration and duration of exposure.

This review explores the mechanisms and clinical trials of topical minoxidil for hair loss but presents no new clinical findings, emphasizing the need for better understanding of hair loss etiology for effective treatments.

This case report describes a 27-year-old woman who experienced facial swelling due to allergic contact dermatitis from using minoxidil 5% foam.